Ablexis, LLC, a San Francisco, California-based biotechnology company dedicated to developing an innovative platform for antibody drug discovery, has completed a $12m Series A financing.
The round was led by Third Rock Ventures, with participation from Pfizer Venture Investments.
The funds will be used to continue advancing Ablexis’ proprietary AlivaMab Mouse transgenic mouse platform for the discovery of human therapeutic antibodies.
In conjunction with the funding, Lou Tartaglia, Ph.D., partner at Third Rock Ventures, will join Larry Green, Ph.D., chief executive officer, and Cary Pfeffer, M.D., partner at Third Rock Ventures, on the company’s board of directors.
FinSMEs
02/06/2010